Moreover, the viral defense gene signature in tumor samples significantly correlated with the long-term clinical outcome of melanoma patients treated with anti-CTLA4 [50], and combination of DNMTi with anti-CTLA4 in the murine B16 melanoma model showed favorable therapeutic response [50]. The gene discussed is CTLA4; the disease is neoplasm.